Kiniksa posts new investor presentation update

Kiniksa Pharmaceuticals International, plc filed a Form 8-K to let investors know it has posted a new investor presentation on its website at investors.kiniksa.com.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc filed a Form 8-K to let investors know it has posted a new investor presentation on its website at investors.kiniksa.com. The company plans to use this presentation, in whole or in part and potentially with modifications, in upcoming meetings with investors, analysts and other audiences.

The investor presentation is furnished as Exhibit 99.1 to this report, with an additional cover page interactive data file listed as Exhibit 104. The filing is informational and does not announce any specific transaction or financial results.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kiniksa Pharmaceuticals International, plc (KNSA) disclose in this Form 8-K?

Kiniksa Pharmaceuticals International, plc disclosed that it has posted a new investor presentation on its website and furnished it as Exhibit 99.1 to this report.

Where can investors find the new Kiniksa (KNSA) investor presentation?

Investors can access the investor presentation on Kiniksa’s website at investors.kiniksa.com and in Exhibit 99.1 attached to the Form 8-K.

How does Kiniksa (KNSA) intend to use the investor presentation?

Kiniksa intends to use the investor presentation, in whole or in part and possibly with modifications, in planned presentations to investors, analysts and others.

Does this Kiniksa (KNSA) Form 8-K announce any new financial results or major transactions?

No, this Form 8-K focuses on the availability and planned use of an investor presentation and does not describe new financial results or major transactions.

What exhibits are included with this Kiniksa (KNSA) Form 8-K?

The filing includes Exhibit 99.1, the Kiniksa investor presentation, and Exhibit 104, the cover page interactive data file embedded within the inline XBRL document.

Who signed this Kiniksa Pharmaceuticals International, plc Form 8-K?

The Form 8-K was signed on behalf of Kiniksa Pharmaceuticals International, plc by Mark Ragosa, Executive Vice President and Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/03/2025 - 07:35 AM Learn about SEC filing dates

false 0001730430 0001730430 2025-09-03 2025-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 3, 2025

Kiniksa Pharmaceuticals International, plc

(Exact name of Registrant as Specified in Its Charter)

England and Wales		001-730430		98-1795578
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

23 Old Bond Street, Floor 3

London, W1S 4PZ

England, United Kingdom

(Address of principal executive offices, including zip code)

(781) 431-9100

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Ordinary Shares, $0.000273235 nominal value		KNSA		The Nasdaq Stock Market LLC
				(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On September 3, 2025, Kiniksa Pharmaceuticals International, plc (the “Company”) posted an investor presentation (the “Investor Presentation”) to its website at investors.kiniksa.com. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with its planned presentations to investors, analysts and others.

A copy of the Investor Presentation is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Kiniksa Pharmaceuticals International, plc Investor Presentation
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
Date: September 3, 2025	By:	/s/ Mark Ragosa
		Mark Ragosa
		Executive Vice President, Chief Financial Officer